Cancer News and Research

Latest Cancer News and Research

Sun and vitamin D levels may play a strong role in risk of type 1 diabetes in children

In this new study, the researchers found that populations living at or near the equator, where there is abundant sunshine (and ultraviolet B irradiance) have low incidence rates of type 1 diabetes. Conversely, populations at higher latitudes, where available sunlight is scarcer, have higher incidence rates.

5 Jun 2008

Arthritis drugs used in children to be investigated because of cancer link

Authorities in the United States are investigating certain types of drugs used to treat arthritis and other conditions.

5 Jun 2008

Synthetic molecules developed by Hebrew University researchers hold promise for new family of anti-cancer drugs

Synthetic molecules designed by two Hebrew University of Jerusalem researchers have succeeded in reducing and even eliminating the growth of human malignant tissues in mice, while having no toxic effects on normal tissue.

4 Jun 2008

Prostate Cancer Foundation 'beefs up' cancer research

The Prostate Cancer Foundation (PCF) has committed more than $19 million in new research funding for scientific investigations focused on discovering new treatments for recurrent prostate cancer. A total of eight programs representing 18 leading research institutions and 36 researchers were selected as part of the foundation's 2008 Challenge Awards. The funded programs will receive the first of three annual payments, ranging between $500,000 and $1.0 million per program, this week.

4 Jun 2008

Long-term pesticide exposure may increase diabetes risk

Licensed pesticide applicators who used chlorinated pesticides on more than 100 days in their lifetime were at greater risk of diabetes, according to researchers from the National Institutes of Health (NIH). The associations between specific pesticides and incident diabetes ranged from a 20 percent to a 200 percent increase in risk, said the scientists with the NIH's National Institute of Environmental Health Sciences (NIEHS) and the National Cancer Institute (NCI).

4 Jun 2008

Tough action against underperforming hospitals and primary care trusts in UK

Health Minister Ben Bradshaw today set out new plans to drive up standards of care and tackle underperformance in our hospitals and primary care trusts.Tough action against underperforming hospitals and trusts

4 Jun 2008

BN ImmunoTherapeutics starts clinical trials with prostate cancer vaccine

BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

4 Jun 2008

Many young children short on vitamin D

A new study by researchers in the United States has found that many young children are lacking in vitamin D.

4 Jun 2008

Single drug treatment a viable option to radiation for early testicular cancer

The results of research into early testicular cancer has found that a single chemotherapy treatment is just as effective as radiation therapy while much less toxic.

4 Jun 2008

New molecular mechanism for colorectal cancer

Scientists in Portugal just found a new molecular mechanism behind colorectal cancer in which a mutated and a normal, but over-expressed, gene cooperate and are both needed to create the disease.

4 Jun 2008

UK cancer research 'punching above its weight'

UK cancer research is helping to deliver significant clinical improvements for cancer patients, according to a study published in the British Journal of Cancer.

4 Jun 2008

Hair cloning technique may be cure for baldness

The ability of scientists to clone hair cells in a laboratory means premature baldness could soon be a thing of the past.

3 Jun 2008

Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with Methotrexate

A chronic, inflammatory disease of unknown origin, rheumatoid arthritis (RA) affects about 1 percent of adults worldwide. Marked by joint destruction, RA often leads to disability and diminished quality of life. It can also lead to an early death from cancer.

3 Jun 2008

U of M sets new standard of care for recessive dystrophic epidermolysis bullosa

Physicians at the University of Minnesota and University of Minnesota Children's Hospital, Fairview have set the path to a cure for a young boy's fatal genetic skin disease, recessive dystrophic epidermolysis bullosa (RDEB), by using a cord blood and bone marrow transplant. Nate Liao, a 25-month-old from Clarksburg, N.J., underwent the experimental therapy in October 2007.

3 Jun 2008

Cephalon files patent infringement case against Watson Pharmaceuticals

Cephalon, Inc. today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II].

3 Jun 2008

A magnetically contolled camera pill

Images from inside the body? It can be done with tiny cameras which the patient has to swallow. In the past there was no way of controlling the device as it passed through the body. Now it can be steered and stopped where desired, and even deliver images of the esophagus.

3 Jun 2008

New 'Track Your Drinking' Google gadget

If you find it difficult to keep track of just how many glasses of wine you've consumed during the week, help is at hand thanks to Cancer Research UK.

3 Jun 2008

Bavarian Nordic enters trials with prostate cancer vaccine

Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

3 Jun 2008

Edward Kennedy has successful surgery for deadly brain tumour

Doctors in the United States treating Senator Edward Kennedy for a brain tumour say he has undergone successful surgery.

3 Jun 2008

ThromboGenics and BioInvent report positive results for anti-PlGF cancer therapeutic TB-403

ThromboGenics NV and co-development partner BioInvent International AB today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer

3 Jun 2008